

RNS Number : 6435D
EKF Diagnostics Holdings PLC
31 March 2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

**EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")**

Director Resignation

As announced on 20 March 2014, EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care diagnostics business, confirms today that Mr Gordon James Hall, a non-executive Director, has stepped down from the Board with immediate effect. The Board wish to thank Mr Hall for his excellent contribution and continue to seek a senior Non-Executive Director to replace Mr Hall.

Enquiries:

EKF Diagnostics Holdings plc
David Evans, Executive Chairman
Julian Baines, CEO
Paul Foulger, CFO

Tel: 029 2071 0570
Mob: 07740 084 452
Mob: 07788 420 859
Mob:07710 989 255

Canaccord Genuity Limited

Tel: 020 7523 8000

Nominated Adviser/Corporate Broking

Lucy Tilley /Julian Feneley /Henry Fitzgerald-O'Connor /Chris Connors

Walbrook PR Limited

Paul McManus

Paul Cornelius

Tel: 020 7933 8780

Mob: 07980 541 893 or

paul.mcmanus@walbrookpr.com

Mob: 07866 384 707 or paul.cornelius@walbrookir.com

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June

2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

This information is provided by RNS
The company news service from the London Stock Exchange

END

BOAJBMATMBIJBTI admin Director Resignation 21577307 A Mon, 03/31/2014 - 16:46 Executive Changes EKF